Every Form 4 that MediWound Ltd. (MDWD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MDWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDWD filings page.
MediWound Ltd. (MDWD) director Samuel Rubinstein reported offsetting indirect trades in ordinary shares held by his spouse on September 1, 2026, selling 525 shares at $12.72 and purchasing 525 shares at $12.62, resulting in no net change in share count. The filing also lists existing equity holdings, including stock options to acquire ordinary shares with exercise prices of $9.64, $12.73, $18.54 and $17.60, covering 7,200; 7,542; 5,600; and 6,250 underlying shares, respectively, plus ordinary shares underlying RSUs that vest one year after a March 4, 2026 grant. Several rows are explicitly described as informational only, with no transactions effected, and no Rule 10b5-1 trading plan is reported.
MediWound Ltd. (MDWD) reported insider option exercises and share sales by Shmuel Hess, COO & Chief Commercial Officer. On August 26–27, 2026 he exercised 16,000 stock options at an exercise price of $8.1292 per share on a net (cashless) basis, receiving 5,823 ordinary shares that were all sold the same days in open-market transactions totaling 5,823 shares at prices between $12.72 and $13.126 per share. He continues to hold several option grants over additional ordinary shares with exercise prices between $12.729 and $18.54 and expirations from 2034 to 2036.
MediWound Ltd. director Nachum Shamir reported buying 6,000 ordinary shares in the open market. The Form 4 shows two purchase transactions on June 3, 2026, involving 5,825 shares at $14.00 per share and 175 shares at $13.975 per share.
Following these purchases, Shamir directly holds 49,990 ordinary shares. He also has 1,200 ordinary shares underlying RSUs that were granted on March 4, 2026 and vest in full one year after the grant date. In addition, he holds several stock option grants and Series A warrants over ordinary shares with exercise prices between $11.8850 and $18.5400, and Series A warrants exercisable at $13.4750 per share through November 28, 2026.
MediWound Ltd. director David Morton Fox reported open-market purchases of a total of 3,537 ordinary shares on June 1, 2026, at prices between $13.995 and $14.23 per share. Other rows in the filing reflect existing holdings only, with no transactions in those securities.
He also holds several equity incentives, including stock options over 6,250 ordinary shares at an exercise price of $17.6000 expiring on March 4, 2036, and Series A warrants over 6,534 ordinary shares at an exercise price of $13.4750 expiring on November 28, 2026. Footnotes state that certain RSUs and options granted on March 4, 2026 vest 100% on the one-year anniversary of that grant date.
MediWound Ltd. director Samuel Rubinstein reported a small open-market purchase of 150 Ordinary Shares of MediWound on May 29, 2026 at $14.33 per share. After this trade, he directly holds 2,993 Ordinary Shares and indirectly holds 525 Ordinary Shares through his spouse.
He also holds several stock option awards giving rights to buy additional Ordinary Shares at exercise prices between $9.64 and $18.54, with expirations from 2033 to 2036. Footnotes clarify that certain ordinary share and option holdings reflect previously granted RSUs and options included for informational purposes, with no transactions occurring in those rows.